-
Review
-
Korean J Med. 2006;71(1):181-181.
- LV, 5FU with/without docetaxel in patients with inoperable or relapsed gastric cancer
-
Kwang-Sun Lee, Sang-Jae Lee, Joung-Soon Jang
-
.
- LV, 5FU with/without docetaxel in patients with inoperable or relapsed gastric cancer
-
, ,
-
가천의과대학교길병원
-
- Abstract
- Purpose
To estimate the effect and toxicity of leucovorin(LV) and fluorouracil(5FU) with/without docetaxel(LV5FU2D/LV5FU2)
combination chemotheraphy in patients with inoperable or postoperative relapsed gastric cancer. Methods Total 27 patients are
enrolled in this study. 8 patients received LV 20mg/m2(bolus), 5FU 400mg/m2(bolus), 5FU 600mg/m2(24-hour continuous
infusion) on day 1, 2, 15, and 16, every 4 weeks(LV5FU2). 19 patients received LV5FU2 plus docetaxel 60mg/m2(1-hour infusion)
on day 15(LV5FU2D). Results A total of 17 cycles of LV5FU2 and 101 cycles of LV5FU2D were administered. Response is
observed only in LV5FU2D group and the response rate were 40.0% with 2 complete response and 4 partial response in 15
evaluable LV5FU2D group patients. The median response duration is 183 days (95% CI, 57-183). As compared with LV5FU2
group, LV5FU2D had a higher likelihood of median time to progression (228 days (95% CI, 58-127) in LV5FU2D, 85 days (95%
CI, 58-127) in LV5FU2; P<0.0001). The grade 3-4 toxcity of neutropenia(24.6%) is observed in LV5FU2D group and of
neutropenia(5.7%), anemia(5.7%) is observed in LV5FU2 group. The grade 1 toxcity of injection site reaction is observed all
patients and the grade 1-2 toxcity of alopecia is observed 60% in LV5FU2D group. Conclusion LV5FU2D significant increase
response and time to progression in patients with inoperable or postoperative relapsed gastric cancer than LV5FU2, and is
observed tolerable toxicity.
Keywords :
